OTLK — Stock Film
STOCK FILMSCENE 1/11OTLK · $0.68
Stock Expert AI presents
OTLK
Outlook Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Outlook Therapeutics, Inc. A quick introduction.

On the stock market since 2016, it operates in the world of health and science. It has 17 employees. Now — the numbers.

on the stock market since 2016
17 employees
$141.4M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $45.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $30.2M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
3 / 8
EXPECTATIONS MET OR BEATEN
3
Dec 2024
Feb 2025
May 2025
Aug 2025
Dec 2025
Feb 2026
May 2026
Aug 2026
3 TIMES IN THE LAST 8 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
63
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
41
weak

Clearly below the class average.

VALUATION
7
very weak

Clearly below the class average.

GROWTH
47
weak

Clearly below the class average.

PRICE MOMENTUM
70
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Each sale is made at a loss3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $1.4M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 32 buys and 2 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $2.80314% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $62.4M against $1.4M in annual sales.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.68. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, OTLK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: OTLK is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (7/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film